Indiamed Globals

• Kidney cancer

Product Description:
Tykerb 250 mg Tablet contains Lapatinib, a tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. Lapatinib targets specific receptors involved in cancer cell growth, particularly the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). By inhibiting these receptors, Tykerb helps to slow down or stop the growth of cancer cells.

Common indications for Tykerb Tablet include:

• HER2-Positive Breast Cancer: Tykerb is used in combination with other medications, such as capecitabine or letrozole, to treat HER2-positive metastatic breast cancer that has not responded to previous therapies.

Dosage and Administration: The usual dosage of Tykerb is determined by the healthcare provider based on the patient’s specific condition and response to treatment. It is important to follow the prescribed dosage and administration schedule as directed.

Common side effects of Tykerb may include:

• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Rash
• Liver enzyme abnormalities

More serious side effects can include potential cardiac issues, severe liver problems, and severe allergic reactions. Regular monitoring and follow-ups with the healthcare provider are essential to manage these potential risks and adjust the treatment as needed.

Packaging: Tykerb 250 mg is typically available in blister packs containing 30 tablets. This packaging helps ensure the medication's stability and allows for convenient dosing.

Tykerb is manufactured by GlaxoSmithKline (GSK), a leading pharmaceutical company known for its high-quality products. It offers a targeted therapy option for managing HER2-positive breast cancer, providing a critical tool for patients with this type of cancer. Regular consultations with healthcare professionals are important for monitoring the effectiveness of the therapy and managing any potential side effects.

Product Description:
Tretinoin CA Atra 10mg Softgel Capsules contain Tretinoin, a derivative of vitamin A, also known as all-trans retinoic acid (ATRA). This medication is used primarily in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia. Tretinoin works by promoting the differentiation of immature blood cells into normal cells, helping to restore normal blood cell production.

In addition to its use in treating APL, Tretinoin is also prescribed for the management of severe acne that has not responded to other treatments. It works by promoting skin cell turnover, reducing the formation of acne and unclogging pores.

Tretinoin softgel capsules are typically part of a combination therapy, particularly in APL treatment, and they are often used alongside other chemotherapy agents. Regular monitoring by a healthcare provider is essential during treatment, and it may take some time to observe the full therapeutic effects

Product Description:
Tagrisso 80mg Tablet contains Osimertinib, a targeted cancer therapy used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR). Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) that works by blocking the activity of the mutated EGFR, which drives the growth and spread of cancer cells. It is particularly effective against NSCLC that has developed resistance to other EGFR inhibitors.

Common indications for Tagrisso 80mg Tablet include:

• Cancer Treatment: Used in the management of non-small cell lung cancer (NSCLC) with specific EGFR mutations.

Dosage and Administration:

• For Adults: The typical dose is one 80 mg tablet taken orally once daily. The exact dosage and duration of treatment are determined by the oncologist based on the patient's condition and response to therapy.
• Administration: Tagrisso should be taken with or without food, and at the same time each day.

Common side effects of Tagrisso 80mg Tablet may include:

• Diarrhea
• Rash
• Dry skin
• Stomatitis (inflammation of the mouth)
• Nail changes

Serious side effects can include interstitial lung disease, QT prolongation (a type of heart rhythm problem), and low blood cell counts. Regular monitoring of lung function, heart function, and blood tests is essential during treatment.

Packaging:
Tagrisso 80mg Tablet is typically packaged in a box containing 30 tablets, with each tablet individually sealed to ensure proper dosage and patient safety.

Tagrisso 80mg Tablet is a vital medication in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It offers a targeted approach that can significantly improve outcomes for patients with this type of cancer. However, due to its potential for serious side effects, it should be used under the guidance and supervision of an experienced oncologist. Regular monitoring of patient health and response to therapy is crucial during treatment with Osimertinib.

• Breast cancer
• Cancer of colon and rectum

• In Breast cancerCapetero 500mg Tablet helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Capetero 500mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.In Cancer of colon and rectumCancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer from two parts of the large intestine, namely, the colon or rectum. In this type of cancer, the person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss, and fatigue. Capetero 500mg Tablet treats and also lowers the risk of developing further cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.

Product Description:
Opdyta 40mg Injection contains Nivolumab, an immune checkpoint inhibitor that targets the programmed death-1 (PD-1) pathway, a mechanism used by cancer cells to avoid being attacked by the immune system. By inhibiting PD-1, Nivolumab reactivates T-cells to recognize and destroy cancer cells. This immunotherapy is used to treat several types of advanced cancers, often in cases where other treatments have failed or are unsuitable.

Common indications for Opdyta 40mg Injection include:

• Melanoma: Used in the treatment of unresectable or metastatic melanoma.
• Non-Small Cell Lung Cancer (NSCLC): Approved for the treatment of metastatic NSCLC after platinum-based chemotherapy.
• Renal Cell Carcinoma (RCC): Used in the treatment of advanced RCC after prior anti-angiogenic therapy.
• Classical Hodgkin Lymphoma: For patients whose disease has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin.
• Head and Neck Cancer: Used in recurrent or metastatic squamous cell carcinoma of the head and neck.
• Urothelial Carcinoma: For patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
• Colorectal Cancer: Used for the treatment of metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.

Dosage and Administration:

• For Adults: The dosage varies based on the type of cancer being treated and the patient's body weight, typically administered as an intravenous infusion over 30 minutes every 2 or 4 weeks.
• Administration: Opdyta is administered as an intravenous infusion by a healthcare professional in a clinical setting. Dosage and frequency depend on the specific condition being treated and patient response.

Common side effects of Opdyta 40mg Injection may include:

• Fatigue
• Nausea
• Rash
• Diarrhea
• Anemia
• Hepatitis
• Colitis

Patients are closely monitored during treatment for potential immune-related adverse effects, which can affect various organs and require immediate medical attention.

Packaging:
Opdyta 40mg Injection is typically packaged in a single-use vial containing 4 mL of solution for infusion, designed for single-dose use.

Opdyta 40mg Injection represents a significant advancement in cancer immunotherapy, offering new treatment options for patients with various types of advanced cancers. By harnessing the body's immune system to fight cancer, Opdyta has become a vital component in the management of cancers that are otherwise difficult to treat. Close monitoring and adherence to the prescribed infusion schedule are crucial for maximizing the benefits of this therapy while managing potential side effects.

Product Description:
Bracanat 150mg Tablet contains Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of various cancers, particularly those associated with BRCA gene mutations. Olaparib works by blocking the PARP enzyme, which helps repair damaged DNA in cells. By inhibiting this enzyme, Olaparib prevents cancer cells from repairing themselves, leading to their death.

Common indications for Bracanat 150mg Tablet include:

• Ovarian Cancer: Used in the maintenance treatment of adult patients with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy.
• Breast Cancer: Used in the treatment of HER2-negative breast cancer with BRCA1/2 mutations.
• Pancreatic Cancer: Used in the maintenance treatment of BRCA-mutated metastatic pancreatic cancer.
• Prostate Cancer: Used in the treatment of metastatic castration-resistant prostate cancer with BRCA1/2 mutations.

Dosage and Administration:

• For Adults: The usual recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily, for a total daily dose of 600 mg.
• Administration: The tablet should be swallowed whole with water, taken at approximately the same times each day, with or without food. It should not be crushed, chewed, or split.

Common side effects of Bracanat 150mg Tablet may include:

• Nausea
• Fatigue
• Anemia
• Vomiting
• Diarrhea
• Loss of appetite

Regular blood tests and monitoring are essential during treatment to manage potential side effects and adjust the dosage as needed.

Packaging:
Bracanat 150mg Tablet is typically packaged in blister packs containing 14 tablets, designed for a one-week course of treatment when taken as prescribed.

Bracanat 150mg Tablet is a significant advancement in cancer treatment, offering targeted therapy for patients with specific genetic mutations. It plays a crucial role in extending survival and improving the quality of life for patients with certain types of advanced cancers, particularly those associated with BRCA mutations. Regular monitoring and adherence to the prescribed regimen are vital to achieving the best possible outcomes.

Product Description:
Ondem 4 Tablet contains Ondansetron 4 mg, a selective serotonin 5-HT3 receptor antagonist. It is primarily used to prevent and treat nausea and vomiting associated with cancer treatments like chemotherapy and radiotherapy, as well as post-operative nausea. By blocking the actions of chemicals that can trigger nausea, Ondem helps ensure patient comfort during medical procedures.

Popular brands like Ondem, Emeset, and Zofran are commonly prescribed for managing nausea and vomiting across various clinical settings. Manufactured by Alkem Laboratories Ltd, Ondem 4 Tablet provides reliable support in preventing nausea and improving patient outcomes

• 500mg CA Cape Tablets 
• we are Dealing In All Types Of Medicine 

• Take this medicine by mouth with a glass of water. Follow the directions on the prescription label. Do not cut, crush or chew this medicine. Take this medicine on an empty stomach, at least 1 hour before or 2 hours after meals. Do not take with food. Take your medicine at regular intervals. Do not take it more often than directed. Do not stop taking except on your doctor's advice. Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed. Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

Product Description:
Imbruvica 140mg Capsule contains Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of several types of blood cancers. Ibrutinib works by blocking BTK, a protein that helps cancer cells survive and grow. By inhibiting this protein, Imbruvica interferes with the growth and spread of cancer cells, particularly in certain types of leukemia and lymphoma.

Common indications for Imbruvica 140mg Capsule include:

• Chronic Lymphocytic Leukemia (CLL): Used as a first-line treatment or in patients who have received at least one prior therapy.
• Small Lymphocytic Lymphoma (SLL): Treated similarly to CLL, targeting the same type of cancer cells.
• Mantle Cell Lymphoma (MCL): Used in patients who have received at least one prior therapy.
• Waldenström's Macroglobulinemia (WM): A rare type of non-Hodgkin lymphoma treated with Imbruvica.
• Marginal Zone Lymphoma (MZL): Used in patients who have received prior treatment with at least one anti-CD20-based therapy.

Dosage and Administration:

• For Adults: The dosage varies depending on the condition being treated but typically involves taking multiple 140 mg capsules to reach a total daily dose of 420 mg or 560 mg, depending on the specific disease.
• Administration: The capsule should be swallowed whole with water, taken once daily at the same time each day. It should not be opened, crushed, or chewed.

Common side effects of Imbruvica 140mg Capsule may include:

• Diarrhea
• Fatigue
• Nausea
• Musculoskeletal pain
• Bruising
• Rash

Imbruvica may also increase the risk of infections and bleeding, so patients should be monitored closely by their healthcare provider throughout the course of treatment.

Packaging:
Imbruvica 140mg Capsule is typically packaged in bottles containing 90 or 120 capsules, designed to last for one or more months of treatment depending on the prescribed dosage.

Imbruvica 140mg Capsule is a critical component in the treatment of certain blood cancers, offering a targeted approach that has significantly improved outcomes for many patients with these conditions. Adherence to the prescribed regimen and close monitoring are crucial to managing the treatment effectively and mitigating potential side effects.

Product Description:
Anaridex (Anastrozole) is a potent aromatase inhibitor used to treat hormone receptor-positive breast cancer in postmenopausal women. By lowering estrogen levels, Anastrozole helps slow down or stop the growth of cancer cells that rely on estrogen to grow.

Indications:

• Hormone receptor-positive breast cancer in postmenopausal women
• Adjuvant treatment of early breast cancer
• Treatment of advanced breast cancer

Dosage and Administration:
Typically, Anaridex is taken once daily, with or without food, as prescribed by a healthcare provider. The standard dose is 1 mg per day.

Common side effects include:

• Hot flashes
• Fatigue
• Joint pain
• Osteoporosis

Product Description: Silofast 8mg Capsules contain Silodosin 8mg, a selective alpha-1 adrenergic receptor antagonist that is primarily used to treat symptoms of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland in men. By relaxing the muscles in the prostate and bladder neck, Silodosin helps relieve symptoms such as difficulty in urination, a weak urine stream, and frequent or urgent urination, allowing smoother urine flow.

Silofast is highly effective in improving urinary symptoms and quality of life for men with BPH. It specifically targets the alpha-1A receptors in the prostate, minimizing the effect on blood pressure compared to other alpha-blockers. This makes it suitable for older patients or those with comorbidities.

Common side effects include dizziness, retrograde ejaculation (where semen enters the bladder instead of exiting through the penis), and a runny or stuffy nose. It is advised to take the capsule with food to reduce the risk of side effects, and patients should avoid operating heavy machinery or driving until they know how the medication affects them.

Silofast 8mg should be used under medical supervision, and patients are encouraged to consult their healthcare provider if they experience any severe side effects or if their symptoms do not improve. Regular follow-ups may be necessary to monitor the progression of BPH and the effectiveness of the treatment.